Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28256300 | 0.87 | LMNA (0.47) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4656026 | 0.87 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL28797837 | 0.87 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1MAPTTDP1 | |
| SCHEMBL29104600 | 0.85 | PAM (0.49) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL27496576 | 0.85 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1MAPTRECQL | |
| SCHEMBL26097613 | 0.85 | GAA (0.43) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6067639 | 0.85 | MEN1 (0.62) | MEN1KMT2ANR1H4ALDH1A1MAPT | |
| SCHEMBL28199414 | 0.84 | SMN1; SMN2 (0.49) | MEN1KMT2ANR1H4ALDH1A1MAPT | |
| SCHEMBL11644271 | 0.84 | ALDH1A1 (0.39) | MEN1KMT2ANR1H4ALDH1A1MAPT | |
| SCHEMBL5285902 | 0.83 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209579-A | Pigment dispersant composition, method for producing same, pigment dispersion, and active energy ray-curable inkjet ink | 大日精化工业株式会社 | 2023-06-02 | — | — | CN | disclosed |
| CN-106620893-B | Materials for ocular disease phototherapy | 爱博诺德(北京)医疗科技股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-108003980-B | Gasoline engine lubricating oil composition and preparation method thereof | 中国石油化工股份有限公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-107540783-B | Acrylate polymer and application thereof, and lubricating oil pour point depressant and preparation method thereof | 中国石油化工股份有限公司 | 2020-02-28 | — | — | CN | disclosed |
| CN-109476956-A | Adhesive composite | 电化株式会社 | 2019-03-15 | — | — | CN | disclosed |
| CN-108884180-A | Composition | 电化株式会社 | 2018-11-23 | — | — | CN | disclosed |
| US-8710264-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-04-29 | — | — | US | disclosed |
| US-8710264-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-04-29 | — | — | US | disclosed |
| EP-2231590-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2012-08-15 | — | — | EP | disclosed |
| EP-2231590-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2012-03-14 | — | — | EP | disclosed |
| US-20120041063-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20100280108-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-04 | — | — | US | disclosed |
| US-20100280108-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-04 | — | — | US | disclosed |
| WO-2009080769-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041063-A2 | ANTITUMORAL COMPOUNDS | TPD52L2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53 | MEN1 191/4885KMT2A 2897/4885NR1H4 889/4885 |
| US-20100280108-A1 | Antitumoral Compounds | TPD52L2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53 | MEN1 191/4885KMT2A 2897/4885NR1H4 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.